Background: Alkylator resistance contributes to treatment failure in high-risk neuroblastoma. Buthionine sulfoximine (BSO) can deplete glutathione and synergistically enhance in vitro sensitivity to the alkylating agent melphalan (L-PAM) for many neuroblastoma cell lines, but optimal use of this combination needs to be defined because clinical responses have been less frequent and not durable.
N euroblastoma, a pediatric malignancy of the sympathetic nervous system, continues to be a therapeutic challenge (1) . Most patients with stage 4 disease diagnosed at age older than 1 year (or younger than 1 y with MYCN amplification) initially respond to therapy, but many ultimately die of recurrent disease that is refractory to chemotherapy (1) (2) (3) (4) (5) . Acquired alkylator resistance is one likely mechanism for treatment failure because current treatment of high-risk neuroblastoma relies heavily on alkylating agents such as cyclophosphamide and melphalan (L-PAM), often in combination with carboplatin or cisplatin (1, (6) (7) (8) . Before disease progression, myeloablative therapy supported by purged autologous hematopoietic stem cell transplantation has shown improved survival for children with high-risk neuroblastoma (6, 9) , especially if followed-up by treatment with high-dose, pulse 13-cis-retinoic acid (6) . The authors have previously shown that sustained resistance (mean LD 90 ‫ס‬ 84 mol/L) to the alkylating agent L-PAM occurs in most cell lines established from patients who experienced relapse after myeloablative therapy that included intensive L-PAM (210 mg/m 2 ) during the preautologous hematopoietic stem cell transplantation conditioning (10, 11) . Therefore, modulation of alkylator resistance is one novel strategy that may improve the efficacy of autologous hematopoietic stem cell transplantation and ultimately increase the rate of survival for children with stage 4 neuroblastoma.
Glutathione is a ubiquitous intracellular tripeptide that protects cells from oxidative stress and has been shown to detoxify alkylating agents (12) (13) (14) . Buthionine sulfoximine (BSO), a specific inhibitor of ␥-glutamyl cysteine synthetase (the rate-limiting enzyme in glutathione synthesis), depletes glutathione and can reverse alkylator resistance (12, (15) (16) (17) (18) . The authors have previously reported that BSO, as a single agent, is highly cytotoxic for neuroblastoma cell lines in vitro and results in apoptosis because of increased generation of reactive oxygen species (19, 20) . Combining BSO with L-PAM at clinically achievable (nonmyeloablative) concentrations is synergistic in neuroblastoma cell lines (20) . Nonmyeloablative trials of BSO and L-PAM in adults have shown the combination to be safe and well tolerated, with reversible bone marrow suppression as the major clinical toxicity (21) (22) (23) (24) . The authors recently completed a pilot clinical trial (NCI #T95-0092) of BSO and low-dose L-PAM in children with recurrent neuroblastoma (25, 26) . A neuroblastoma cell line (CHLA-171) was established from a postmortem blood specimen of a patient treated on this regimen who ultimately died of recurrent disease. The authors show here that CHLA-171 is resistant to BSO and L-PAM as single agents and that BSO can synergistically reverse L-PAM resistance, but only at high levels of L-PAM that are achievable in the myeloablative setting.
MATERIALS AND METHODS

Patient History and Cell Line Characteristics
The patient was an 8-year-old girl with a stage 4 MYCN nonamplified neuroblastoma. Histology was classified as unfavorable by the criteria of Shimada et al. (27) (maturing ganglioneuromatous stroma with nodules of poorly differentiated neuroblastoma); and urine catecholamine and serum ferritin levels were increased. The patient achieved a very good partial response (28, 29) on the Children's Cancer Group high-risk neuroblastoma protocol CCG-3891, randomized to chemotherapy consolidation and 13-cis-retinoic acid (6, 30) .
The tumor recurred and the patient received two courses of vincristine, doxorubicin, and cyclophosphamide (31) , with no response. The patient was then treated with two courses of BSO/L-PAM (NCI #T95-0092; BSO 3 g/m 2 bolus followed-up by continuous infusion of 0.75 mg/m 2 per hr × 72 hr; L-PAM 15 mg/m 2 bolus at hr 48 of therapy) (25, 26) .
Pharmacokinetics performed on this patient showed a peak plasma concentration of 3.90 mol/L L-PAM and a steady-state concentration of 397 mol/L L-(S,R) BSO. The disease recurred after the second course of BSO/L-PAM and bone pain required palliative radiotherapy. On the third day of radiation, a severe headache developed. Magnetic resonance imaging of the brain showed extensive metastatic disease in the dura. The patient subsequently received a complete course of irradiation to whole brain (2,340 cGy), total pelvis (3,000 cGy), and lower extremities (1,800 cGy), and ultimately died 21 months after the initial diagnosis.
The postmortem examination was conducted 3 hours after death, and metastatic tumor tissue from the lung parenchyma and 50 mL heparinized blood (mononuclear cells isolated by Lymphocyte Separation Medium, Organon Teknika, Durham, NC, U.S.A.) from the left ventricle were cultured in Iscove-modified Dulbecco medium (Bio Whittaker, Walkersville, MD, U.S.A.) supplemented with 2 mmol/L L-glutamine (Gemini Bioproducts, Calabasas, CA, U.S.A.), 16.6 mg/mL each of insulin and transferrin, 16.6 g/mL selenious acid (ITS culture supplement; Collaborative Biomedical Products, Bedford, MA, U.S.A.), and 20% heat-inactivated fetal bovine serum at 37°C in a 5% CO 2 incubator (STERI-CULT 200; Forma Scientific, Marietta, OH, U.S.A.). Gentamicin (100 g/mL) was used only during the first week of establishing the cell line; thereafter, no further antibiotics were used to facilitate detection of mycoplasma. No cell line resulted from tumor taken from the lung parenchyma. The cell line (CHLA-171) grew from the postmortem blood sample and was used at passage 10 to 20 for all experiments in this report.
Chemicals
The L-PAM (NSC #14210) and L-(S,R) BSO (NSC #326321) were provided by the National Cancer Institute. A 3.3-mmol/L stock solution of L-PAM was made in 0.1 N NaCl/ethanol (unfiltered). A 10-mmol/L stock solution of BSO was made, dissolved in distilled water, and passed through a 0.22-m filter. Stock solutions were made fresh for each experiment. Final dilutions of both drugs were made in Iscove medium with 10% heat-inactivated fetal bovine serum and, as required, adjusted to pH 7.4 with 0.1 NHCl or NaOH. All other chemicals were purchased from Sigma (St. Louis, MO, U.S.A.).
Cytotoxicity Assays
Cell viability after drug treatment was performed in 96-well plates using a novel digital image microscopy (DIMSCAN) system that has a dynamic range of 4 logs of cell kill (32) . Comparison studies have shown viable cells measured by DIMSCAN exclude trypan blue and are clonogenic (33) , and drug sensitivity/resistance as measured by DIMSCAN correlates with clinical drug exposure (10, 11, 34) .
After incubation with drugs or control medium, a vital stain, fluorescein diacetate (10 g/mL), was added to the 96-well plate and incubated for 20 minutes. Eosin-Y (800 g/mL) was then added to quench background fluorescence in the medium and in nonviable cells. The plates were then analyzed on an inverted microscope, with the relative fluorescence of each well quantified by the digital imaging system software designed for the DIMSCAN system. The mean fluorescence for treated wells was compared with control wells to derive the surviving fraction.
Dose-Response Assays
After plating, cells were exposed to various concentrations of L-(S,R) BSO (0-1,000 mol/L) and incubated for 24 hours before the addition of L-PAM (0-40 mol/L). Cytotoxicity was evaluated by DIMSCAN after an additional 7-day incubation. In vitro exposure to L-PAM without drug washout is an appropriate model for clinical application because of the short half-life of L-PAM in tissue culture conditions (35) . The dose ranges for both BSO and L-PAM were based on peak (L-PAM) or steady-state (BSO) plasma concentrations from standard and myeloablative human trials (Table 1) .
Dose Effect Analysis
Cytotoxicity assays were performed by DIMSCAN as described previously. After incubation, the fraction of cells affected (F a ) was calculated [F a ‫ס‬ 1 − (relative fluorescence condition/relative fluorescence control)] from relative fluorescence values obtained using DIMSCAN. Data from individual dose-response studies were analyzed using a single-drug dose-response software program to calculate lethal concentration (LC) values (36) , with LC 50 , LC 75 , and LC 90 defined as the respective concentration of drug required to kill 50%, 75%, or 90% of cells tested. Similarly, synergy between L-PAM and BSO was calculated using fixed ratio (BSO:L-PAM at 10:1) analysis (36) (37) (38) (39) , with synergy defined as a combination index <1. Synergy was also calculated by fixed-ratio analysis (BSO:L-PAM at 10:1) to generate computer-simulated isobolograms at values of LC 50 , LC 75 , and LC 90 (36) (37) (38) (39) . Dose combinations (L-PAM and BSO, respectively) for synergy testing were 3 and 30, 10 and 100, 20 and 200, 30 and 300, and 40 and 400 mol/L.
Glutathione
Glutathione studies were conducted in 12.5-cm tissue culture flasks (2 × 10 6 cells/flask) containing 0, 5, 50, 500, and 1,000 mol/L BSO for 24 hours. Cells were then detached with Pucks Saline A plus 1 mol/L edetic acid, harvested with a Pasteur pipette (Fisher Scientific, Pittsburgh, PA, U.S.A.), washed in isotonic (6.3 mmol/L edetic acid, pH 7.4) phosphate-buffered saline, and centrifuged for 3 minutes at 16,000 g, and the resulting pellet was acidified by 200 L 5% sulfosalicylic acid. After recentrifugation for 3 minutes at 16,000 g, the supernatant was flash-frozen in liquid nitrogen and analyzed for total glutathione content within 48 hours by the DTNB (5,5Ј-dithiobis-2-nitrobenzoic acid-GSSG) glutathione reductase method using 96-well plates and a Thermomax microplate reader for 2 minutes at 405 nm, with results normalized to total protein (40) . Glutathione data previously reported (20) 
Analysis of Plasma Buthionine Sulfoximine and Melphalan Levels
Plasma L-(S,R) BSO was measured by a modified highperformance liquid chromatography technique for ␣-difluoromethylornithine, as previously described (21) . This method uses a precolumn derivativization with ophthalaldehyde, followed-up by gradient elution with phosphate buffer (pH 7.5) and methanol. Plasma L-PAM was measured by high-performance liquid chromatography per the method previously described (21) .
Polymerase Chain Reaction and Reverse Transcription Polymerase Chain Reaction
As previously described (10), quantitative fluorescent polymerase chain reaction was used to determine MYCN genomic amplification. Tyrosine hydroxylase expression and P-glycoprotein 9.5 expression were determined by reverse transcription polymerase chain reaction (10) . Tyrosine hydroxylase expression in a cell line from a childhood small round cell tumor is specific for neuroblastoma, whereas strong P-glycoprotein 9.5 expression is restricted to neural tumors (41) .
Detection of Surface Antigens
To confirm neuroblastoma origin, flow cytometry was used to determine the binding of the neuroblastomaassociated monoclonal antibodies HSAN 1.2 (42) and anti-GD2 (14G2A) (43) . In addition, binding of antihuman leukocyte antigen class I antibody W6-32 (42) was analyzed by flow cytometry, as previously described (10). ‡Indicates levels reported for multiple dose levels.
TABLE 1. Plasma levels of L-PAM and L-(S,R) BSO
RESULTS
Pathology Results and Characterization of CHLA-171
The autopsy revealed extensive multiorgan metastasis of neuroblastoma, including marked infiltration of lung parenchyma, pleura, and epidural space. Histologic analyses showed a stroma-poor, undifferentiated tumor without neuroblastic maturation in lung parenchyma, liver, bone marrow, and epidural space. Mononuclear cells isolated from postmortem left ventricular blood grew attached colonies of tumor cells that proliferated continuously and were designated as CHLA-171.
Cells from CHLA-171 and frozen samples of postmortem tumor were analyzed for genomic amplification of MYCN by polymerase chain reaction, and no amplification was detected. Reverse transcription polymerase chain reaction showed that both CHLA-171 and postmortem tumor tissue were positive for expression of the neural tumor marker PGP 9. 
Cytotoxicity Assays of Buthionine Sulfoximine and Melphalan as Single Agents and in Combination
The results of the cytotoxicity assays by DIMSCAN for L-PAM and BSO as single agents are shown in Figure 1 . CHLA-171 was moderately resistant (LC 50 42.0 mol/L, LC 90 509 mol/L) to L-(S,R) BSO at concentrations corresponding to plasma levels in nonmyeloablative clinical trials (Table 1) , with 1,000 mol/L producing 1.4 logs of cytotoxicity. Similarly, when exposed to a range of concentrations corresponding to plasma L-PAM levels reported for both standard and myeloablative therapy, CHLA-171 was highly resistant to L-PAM (LC 50 4.1 mol/L, LC 90 42.3 mol/L), with 40 mol/L L-PAM resulting in 0.98 logs of cytotoxicity.
Cytotoxicity Assays of Buthionine Sulfoximine Combined With Melphalan
The dose-response curve of L-PAM in combination with a constant level of 500 mol/L is shown in Figure 1 . Throughout all doses ranges of L-PAM , cytotoxicity was enhanced by the addition of 500 mol/L BSO. However, despite being combined with 500 mol/L BSO, the nonmyeloablative concentration of 3 mol/L L-PAM resulted in only 1.45 logs of cytotoxicity. To determine whether BSO and L-PAM achieved synergistic cytotoxicity for CHLA-171, a fixed-ratio (10:1) analysis was performed to determine the combination index for each drug mixture (Fig. 2) . When BSO at 30 mol/L was coincubated with the nonmyeloablative L-PAM concentration of 3 mol/L, no evidence of synergy (combination index ‫ס‬ 1.38) was observed. At all other combinations tested, especially with concentrations of L-PAM that clinically can be achieved only in the myeloablative setting, L-PAM and BSO showed a high degree (combination index <0.3) of drug synergy. The highest concentrations of L-PAM and BSO tested caused significant cytotoxicity for CHLA-171, with 400 mol/L BSO and 40 mol/L L-PAM producing 4.3 logs of cell kill. Synergy was also observed by generating isobolograms for LC 50 , LC 75 , and LC 90 (not shown).
Glutathione Decreased by Buthionine Sulfoximine
CHLA-171 was incubated in various concentrations of BSO (0-1,000 mol/L) for 24 hours and then assayed for 
DISCUSSION
CHLA-171 represents a novel neuroblastoma cell line established from a patient who experienced relapse after BSO/L-PAM therapy. Clinically, the tumor metastasized to locations (e.g., lung parenchyma, pleural, dura) rarely seen in newly diagnosed neuroblastoma (5) . Tumor recurrence in such sites is more common after myeloablative therapy than at diagnosis (central nervous system, 5% vs. 0.6%; lung, 7% vs. 3%) (5, 44, 45) , suggesting that changes conferring drug resistance in neuroblastoma may enhance tumor survival in certain tissues.
CHLA-171 showed a marked resistance to L-PAM that is consistent with our previous report of L-PAM resistance in neuroblastoma cell lines established at the time of recurrence after myeloablative therapy with L-PAM (10). The authors have recently shown that unlike drug-sensitive neuroblastoma cell lines (which have functional p53), most of the neuroblastoma cell lines (including CHLA-171) that show a high level of multidrug resistance (including L-PAM) do not have functional p53 (44) . Thus, L-PAM resistance in CHLA-171 may be mediated, at least in part, by a loss of p53 function. Moreover, the authors have shown here that depletion of glutathione with BSO can be combined with high levels of L-PAM to overcome drug resistance in the CHLA-171 cell line, suggesting that such an approach may be active against tumors lacking functional p53.
Melphalan as a single agent had an LC 90 of 42 mol/L for CHLA-171, compared with the our previous report showing that neuroblastoma cell lines established from patients at the time of diagnosis are sensitive to L-PAM, with a mean LC 90 of 5.2 ± 6 mol/L (10). In the same study, neuroblastoma cell lines established from patients who had relapse after standard chemotherapy were moderately resistant to L-PAM (LC 90 27.3 ± 30 mol/L), and neuroblastoma cell lines obtained from patients who had relapse after high-dose L-PAM (210 mg/m 2 ) supported by bone marrow transplant were extremely resistant to L-PAM (LC 90 273 ± 530 mol/L) (10,11). In our recently completed nonmyeloablative phase I trial of L-PAM and BSO, we observed peak plasma concentrations for L-PAM of 2.3 to 3.9 mol/L (25) . The data presented in this report show that for the patient from whom CHLA-171 was established, L-PAM, both as a single agent and combined with BSO, would be ineffective at the doses used. This resistance was not caused by a failure of BSO to deplete glutathione in CHLA-171 because there was no discernible difference in glutathione levels (baseline and percentage depletion) between CHLA-171 and 10 other neuroblastoma cell lines. However, the current data suggest that a multilog tumor cell kill may have occurred if BSO had been used with doses of L-PAM achievable only in the myeloablative setting.
Our current clinical data in neuroblastoma for BSO/L-PAM (25) , and the results from studying the CHLA-171 cell line, suggest that neuroblastoma can develop a marked and sustained resistance to L-PAM, and that glutathione depletion with BSO will not overcome that resistance at L-PAM levels that can be obtained in the nonmyeloablative setting. However, the data from CHLA-171 suggest that BSO can overcome L-PAM resistance if the L-PAM dose can be increased with hematopoietic stem cell support. Thus, if BSO/L-PAM is tolerable in the myeloablative setting, BSO may enhance the activity of L-PAM against drug-resistant neuroblastoma and could improve the outcome for patients with neuroblastoma undergoing myeloablative therapy after progressive disease develops. A clinical trial to determine the maximally tolerated dose of L-PAM administered together with BSO and supported with autologous hematopoietic stem cell transplantation is underway.
